持续炎症-免疫抑制-分解代谢综合征研究新进展

李辉凤; 王铭; 潘险峰

doi:10.13201/j.issn.1009-5918.2022.03.012

持续炎症-免疫抑制-分解代谢综合征研究新进展

- 1.
  昆明医科大学(昆明，650000)
- 2.
  联勤保障部队第九二〇医院急诊医学科

详细信息

通讯作者: 潘险峰，E-mail：xianfengpan@outlook.com

中图分类号: R459.7

收稿日期: 2021-10-19

刊出日期: 2022-03-10

New research progress of persistent inflammation- immunosuppression-catabolic syndrome

More Information

Corresponding author: PAN Xianfen, E-mail: xianfengpan@outlook.com

Received Date: 19 October 2021

Publish Date: 10 March 2022

摘要

- 持续炎症-免疫抑制-分解代谢综合征 /
- 慢性危重病 /
- 炎症 /
- 免疫抑制
Abstract: Persistent inflammatory-immunosuppressive-catabolic syndrome(PICS) is a group of clinical syndromes characterized by persistent inflammatory response, immunosuppression and the protein catabolic responses, which develops into chronic critical illness(CCI) after severe trauma, infection, burn and other major diseases. Because its pathogenesis is complex and clinical prevention and treatment is difficult, PICS is the main cause of prolonged hospitalization and long-term death of patients in intensive care unit(ICU). The decline of their quality of life requires long-term acute cares(LTACs), and will eventually experience chronic failure and death. However, the pathogenesis of PICS is complex, clinicians are relatively lack of awareness and vigilance of PICS, resulting in a high incidence and poor long-term prognosis. Therefore, how to improve clinicians' vigilance to PICS and effectively improve the survival rate of patients after discharge has become a great challenge for contemporary medicine. The main purpose of this paper is to summarize the pathogenesis, diagnosis and treatment strategies of PICS by combing the understanding of PICS at home and abroad, and thus improve clinicians' understanding of PICS and provide new ideas for prevention and treatment.
- persistent inflammatory-immunosuppressive-catabolic syndrome /
- chronic critical illness /
- inflammation /
- immunosuppression

HTML全文

参考文献(46)

[1]	Mira JC, Brakenridge SC, Moldawer LL, et al. Persistent Inflammation, Immunosuppression and Catabolism Syndrome[J]. Crit Care Clin, 2017, 33(2): 245-258. doi: 10.1016/j.ccc.2016.12.001
[2]	Eiseman B, Beart R, Norton L. Multiple organ failure[J]. Surg Gynecol Obstet, 1977, 144(3): 323-326.
[3]	Simpson SQ. SIRS in the Time of Sepsis-3[J]. Chest, 2018, 153(1): 34-38. doi: 10.1016/j.chest.2017.10.006
[4]	Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS[J]. Crit Care Med, 1996, 24(7): 1125-1128. doi: 10.1097/00003246-199607000-00010
[5]	Hawkins RB, Raymond SL, Stortz JA, et al. Chronic Critical Illness and the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome[J]. Front Immunol, 2018, 9: 1511. doi: 10.3389/fimmu.2018.01511
[6]	Nelson JE, Cox CE, Hope AA, et al. Chronic critical illness[J]. Am J Respir Crit Care Med, 2010, 182(4): 446-454. doi: 10.1164/rccm.201002-0210CI
[7]	Gentile LF, Cuenca AG, Efron PA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care[J]. J Trauma Acute Care Surg, 2012, 72(6): 1491-1501. doi: 10.1097/TA.0b013e318256e000
[8]	Stortz JA, Raymond SL, Mira JC, et al. Murine Models of Sepsis and Trauma: Can We Bridge the Gap?[J]. Ilar J, 2017, 58(1): 90-105. doi: 10.1093/ilar/ilx007
[9]	Cecconi M, Evans L, Levy M, et al. Sepsis and septic shock[J]. Lancet, 2018, 392(10141): 75-87.
[10]	Schrijver IT, Théroude C, Roger T. Myeloid-Derived Suppressor Cells in Sepsis[J]. Front Immunol, 2019, 10: 327. doi: 10.3389/fimmu.2019.00327
[11]	Savva A, Roger T. Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases[J]. Front Immunol, 2013, 4: 387.
[12]	Mathias B, Delmas AL, Ozrazgat-Baslanti T, et al. Human Myeloid-derived Suppressor Cells are Associated With Chronic Immune Suppression After Severe Sepsis/Septic Shock[J]. Ann Surg, 2017, 265(4): 827-834. doi: 10.1097/SLA.0000000000001783
[13]	Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+)population induces T cell suppression and Th2 polarization in sepsis[J]. J Exp Med, 2007, 204(6): 1463-1474. doi: 10.1084/jem.20062602
[14]	Loftus TJ, Mohr AM, Moldawer LL. Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult[J]. Curr Opin Hematol, 2018, 25(1): 37-43. doi: 10.1097/MOH.0000000000000395
[15]	Darden DB, Kelly LS, Fenner BP, et al. Dysregulated Immunity and Immunotherapy after Sepsis[J]. J Clin Med, 2021, 10(8): 1742. doi: 10.3390/jcm10081742
[16]	Monk DN, Plank LD, Franch-Arcas G, et al. Sequential changes in the metabolic response in critically injured patients during the first 25 days after blunt trauma[J]. Ann Surg, 1996, 223(4): 395-405. doi: 10.1097/00000658-199604000-00008
[17]	Puthucheary ZA, Rawal J, McPhail M, et al. Acute skeletal muscle wasting in critical illness[J]. Jama, 2013, 310(15): 1591-1600. doi: 10.1001/jama.2013.278481
[18]	Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity[J]. Cell Res, 2015, 25(7): 771-784.
[19]	Sheinenzon A, Shehadeh M, Michelis R, et al. Serum albumin levels and inflammation[J]. Int J Biol Macromol, 2021, 184: 857-862. doi: 10.1016/j.ijbiomac.2021.06.140
[20]	Bharadwaj S, Ginoya S, Tandon P, et al. Malnutrition: laboratory markers vs nutritional assessment[J]. Gastroenterol Rep(Oxf), 2016, 4(4): 272-280.
[21]	Lakhan SE, Vieira KF. Nutritional therapies for mental disorders[J]. Nutr J, 2008, 7: 2. doi: 10.1186/1475-2891-7-2
[22]	You JW, Lee SJ, Kim YE, et al. Association between weight change and clinical outcomes in critically ill patients[J]. J Crit Care, 2013, 28(6): 923-927. doi: 10.1016/j.jcrc.2013.07.055
[23]	Hesselink L, Hoepelman RJ, Spijkerman R, et al. Persistent Inflammation, Immunosuppression and Catabolism Syndrome(PICS)after Polytrauma: A Rare Syndrome with Major Consequences[J]. J Clin Med, 2020, 9(1): 191.
[24]	Spijkerman R, Hesselink L, Hellebrekers P, et al. Automated flow cytometry enables high performance point-of-care analysis of leukocyte phenotypes[J]. J Immunol Methods, 2019, 474: 112646. doi: 10.1016/j.jim.2019.112646
[25]	Hagen IV, Helland A, Bratlie M, et al. TMAO, creatine and 1-methylhistidine in serum and urine are potential biomarkers of cod and salmon intake: a randomised clinical trial in adults with overweight or obesity[J]. Eur J Nutr, 2020, 59(5): 2249-2259. doi: 10.1007/s00394-019-02076-4
[26]	Wijntjes J, van Alfen N. Muscle ultrasound: Present state and future opportunities[J]. Muscle Nerve, 2021, 63(4): 455-466. doi: 10.1002/mus.27081
[27]	Groot M, Lee H. Sorting Mechanisms for MicroRNAs into Extracellular Vesicles and Their Associated Diseases[J]. Cells, 2020, 9(4): 1044. doi: 10.3390/cells9041044
[28]	王韫文, 赵敏. 乌司他丁对脓毒症休克导致多器官功能衰竭的保护作用[J]. 医学综述, 2020, 26(1): 101-106. https://www.cnki.com.cn/Article/CJFDTOTAL-YXZS202001021.htm
[29]	刘霁云, 楚尧娟, 师莹莹, 等. 血必净注射液研究现状和热点的可视化分析[J]. 中国医院药学杂志, 2021, 41(15): 1573-1580, 1590-1590. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ202115017.htm
[30]	Liang C, Qiao G, Liu Y, et al. Overview of all-trans-retinoic acid(ATRA)and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia[J]. Eur J Med Chem, 2021, 220: 113451.
[31]	苏和毅, 莫泽珣, 陈蕊, 等. 胸腺肽α1干预治疗对脓毒症后的PICS老年患者免疫、代谢功能及预后的影响[J]. 实用医学杂志, 2018, 34(1): 119-123. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201801033.htm
[32]	Monaghan KL, Wan ECK. The Role of Granulocyte-Macrophage Colony-Stimulating Factor in Murine Models of Multiple Sclerosis[J]. Cells, 2020, 9(3): 611.
[33]	Castro F, Cardoso AP, Gonçalves RM, et al. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion[J]. Front Immunol, 2018, 9: 847.
[34]	Khairil Anwar NA, Mohd Nazri MN, Murtadha AH, et al. Prognostic prospect of soluble programmed cell death ligand-1 in cancer management[J]. Acta Biochim Biophys Sin(Shanghai), 2021, 53(8): 961-978.
[35]	李盼, 马莉. 持续性炎症-免疫抑制-分解代谢综合征发病机制及诊疗的新进展[J]. 中华重症医学电子杂志(网络版), 2020, 6(3): 318-321. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYD202003015.htm
[36]	Xiao Z, Li J, Yu Q, et al. An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma[J]. Front Pharmacol, 2021, 12: 778294.
[37]	Al-Majed AA, Bakheit AHH, Abdel Aziz HA, et al. Propranolol[J]. Profiles Drug Subst Excip Relat Methodol, 2017, 42: 287-338.
[38]	Weijs PJM. Protein nutrition and exercise survival kit for critically ill[J]. Curr Opin Crit Care, 2017, 23(4): 279-283.
[39]	Martin AD, Smith BK, Davenport PD, et al. Inspiratory muscle strength training improves weaning outcome in failure to wean patients: a randomized trial[J]. Crit Care, 2011, 15(2): R84.
[40]	Moore FA, Phillips SM, McClain CJ, et al. Nutrition Support for Persistent Inflammation, Immunosuppression, and Catabolism Syndrome[J]. Nutr Clin Pract, 2017, 32(1_suppl): 121s-127s.
[41]	Morris SM Jr. Arginine Metabolism Revisited[J]. J Nutr, 2016, 146(12): 2579s-2586s.
[42]	Hernandez-García AD, Columbus DA, Manjarín R, et al. Leucine supplementation stimulates protein synthesis and reduces degradation signal activation in muscle of newborn pigs during acute endotoxemia[J]. Am J Physiol Endocrinol Metab, 2016, 311(4): e791-e801.
[43]	Thaiss CA, Zmora N, Levy M, et al. The microbiome and innate immunity[J]. Nature, 2016, 535(7610): 65-74.
[44]	Fan J, Wu J, Wu LD, et al. Effect of parenteral glutamine supplementation combined with enteral nutrition on Hsp90 expression and Peyer's patch apoptosis in severely burned rats[J]. Nutrition, 2018, 47: 97-103.
[45]	Seufferlein T, Kleger A, Nitschmann S. Recurrent Clostridium difficile infection. Treatment with duodenal infusion of donor feces[J]. Internist(Berl), 2014, 55(4): 455-459.
[46]	Zaborin A, Defazio JR, Kade M, et al. Phosphate-containing polyethylene glycol polymers prevent lethal sepsis by multidrug-resistant pathogens[J]. Antimicrob Agents Chemother, 2014, 58(2): 966-977.